01.08.2024 • News

Arkema Opens Innovation Lab for Light-Curable Specialties in Japan

French specialty materials manufacturer Arkema has opened its new technologies innovation lab for ultraviolet-light-cured (UV-cured), light emitting diode (LED-cured) and electron-beam-cured (EB-cured) curable resins and additives for specialty coating and adhesive applications at the company’s Kyoto Technical Center (KTC).

This strategic move, Arkema said, strengthens its ability to innovate and address customer needs for advanced electronics, new energies, building efficiency and e-mobility markets.

“This expansion will strengthen the development of Arkema’s portfolio of solutions synergies and innovation; as well as to promote Sartomer UV-LED and EB curing technologies, which are very low VOC and lower carbon intensive, in Japan. The new UV-LED-EB lab will accelerate the development of local sustainable solutions that will support local and global customers to design their next generation of solutions,” commented Shinichi Sato, president and representative director of Arkema in Japan.

Damien Vitry, general manager of the Arkema’s Kyoto Technical Center, added: “The opening of the new Arkema UV specialties research and development lab at Arkema Kyoto Technical Center is a great opportunity both for our teams and for our customers to fully benefit from a wider range of expertise and to accelerate our new developments and innovation in Japan.”

© Getty Images/iStockphoto
© Getty Images/iStockphoto

Company

Logo:

Arkema

420 rue d’Estienne d’Orves
92705 Colombes Cedex
France

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read